Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer

Published:2016-07-13 Issue:1 Volume:16 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Cleary James M.,Mamon Harvey J.,Szymonifka Jackie,Bueno Raphael,Choi Noah,Donahue Dean M.,Fidias Panos M.,Gaissert Henning A.,Jaklitsch Michael T.,Kulke Matthew H.,Lynch Thomas P.,Mentzer Steven J.,Meyerhardt Jeffrey A.,Swanson Richard S.,Wain John,Fuchs Charles S.,Enzinger Peter C.

Funder

Pharmacia Oncology

National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-016-2485-9.pdf

Reference47 articles.

1. Enzinger PC, Mayer RJ. Esophageal Cancer. N Engl J Med. 2003;349(23):2241–52. doi: 10.1056/NEJMra035010 .

2. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681–92. doi: 10.1016/s1470-2045(11)70142-5 .

3. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8(3):226–34. doi: 10.1016/S1470-2045(07)70039-6 .

4. Rizk NP, Venkatraman E, Bains MS, Park B, Flores R, Tang L, et al. American Joint Committee on Cancer Staging System Does Not Accurately Predict Survival in Patients Receiving Multimodality Therapy for Esophageal Adenocarcinoma. J Clin Oncol. 2007;25(5):507–12. doi: 10.1200/jco.2006.08.0101 .

5. Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, et al. Complete Response to Neoadjuvant Chemoradiotherapy in Esophageal Carcinoma Is Associated With Significantly Improved Survival. J Clin Oncol. 2005;23(19):4330–7. doi: 10.1200/jco.2005.05.017 .

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The role of lipid metabolism in cancer radioresistance;Clinical and Translational Oncology;2023-04-20

2. Perspectives of the Application of Non-Steroidal Anti-Inflammatory Drugs in Cancer Therapy: Attempts to Overcome Their Unfavorable Side Effects;Cancers;2023-01-12

3. Management of Oligometastatic Disease in Esophagogastric Cancer: What Is the Evidence?;Oncology Research and Treatment;2023

4. A Seed in the Soil — Isolated Esophageal Cancer Recurrence in the Brain After Trimodality Treatment is more Common than Expected but Associated with Better Outcomes;Journal of Gastrointestinal Cancer;2022-11-18

5. Incidence of Brain Metastasis as First Event in Patients with Esophageal Carcinoma: a Report from Three Prospective Alliance Clinical Trials;Journal of Gastrointestinal Cancer;2022-10-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3